Press Releases
Latest ¦ 2011 ¦ 2010 ¦ Archive
January 30, 2012
Concert Pharmaceuticals to Present at Epilepsy Pipeline Update Conference
January 18, 2012
New Patents Expand Concert Pharmaceuticals’ Patent Estate of Deuterium-Based Therapeutics; 25 Patents Issued Worldwide
January 3, 2012
Concert Pharmaceuticals to Present at the J.P. Morgan Healthcare
Conference on January 10, 2012
[ back to top ]
November 21, 2011
Concert Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference on November 30, 2011
November 15, 2011
Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases
November 14, 2011
Concert Pharmaceuticals Presents Preclinical Data for Novel GABA(A) Subtype-Selective Modulator at Neuroscience 2011; Potential Treatment for Multiple GABA-Based Disorders Including Spasticity and Pain
November 14, 2011
Concert Presents Phase 1 Data for CTP-499 at ASN Kidney Week Meeting; Supports Advancement into Phase 2 in Diabetic Nephropathy Patients
October 19, 2011
Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
October 19, 2011
Concert Pharmaceuticals Announces Data Presentations at Neuroscience
2011; Demonstrates Potential of Deuterium-Containing GABAA Modulators
September 29, 2011
Concert Pharmaceuticals Announces Issuance of 15th US Patent Supporting DCE Platform™ Approach; Receives New Patent for Use of C-21191 in Spasticity
August 9, 2011
Concert Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
July 20, 2011
Concert Pharmaceuticals’ Deuterium-Modified Boceprevir Demonstrates Enhanced Metabolic Stabilization and Improved Drug Properties; Findings Published in Journal of Labelled Compounds and Radiopharmaceuticals
June 20, 2011
Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
June 20, 2011
Concert Pharmaceuticals Announces Advancement of Novel Drug
Candidates in Kidney Disease and Spasticity
May 2, 2011
Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference; Sigma-1 Agonist, C-10068, Shown to Have Anti-Convulsant and Neuroprotective Effects
April 12, 2011
Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments
Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance; LuAnn Sabounjian Named Vice President, Clinical Operations
March 29, 2011
Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study; First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
March 29, 2011
Concert Pharmaceuticals to Present at the Needham Healthcare Conference on April 5, 2011
March 1, 2011
Concert Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference on March 8
February 2, 2011
Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound; Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries
January 19, 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals; Additional Management Team Announcement with Promotion of Robert Silverman
January 13, 2011
New Patents Continue to Issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property Estate
[ back to top ]
November 2, 2010
Concert Pharmaceuticals Awarded $488,000 Therapeutic Discovery Project Grants
October 27, 2010
Concert Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference on November 3, 2010
September 9, 2010
Concert Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference on September 16, 2010
August 10, 2010
Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development
August 3, 2010
Concert Pharmaceuticals to Present at Canaccord Genuity Global Growth Conference on August 10, 2010
May 20, 2010
Finalists for Ernst & Young Entrepreneur Of The Year® 2010 Awards in New England Announced; Roger Tung Named a Finalist
April 28, 2010
Concert Pharmaceuticals to Participate in Drug Discovery and Development Panel at 2010 BIO International Convention
April 15, 2010
Ernst & Young Entrepreneur Of The Year Award Semi-Finalists in New England announced; Roger Tung Selected a Semi-finalist
March 31, 2010
Concert Pharmaceuticals
Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
March 1, 2010
Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8
January 4, 2010
Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
[ back to top ]
|
